Dynavax Technologies Corporation (DVAX) Stock Analysis
DELISTED 2026
What happened to Dynavax Technologies Corporation (DVAX) stock?
Dynavax Technologies Corporation (DVAX) no longer trades on public markets. It was delisted in February 2026. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- February 2026
- Last recorded price (historical):
- $15.50 (last quote on record before the February 2026 delisting; historical, not a current quote)
P/E 39.74 means the share price is 39.74 times one year of earnings per share. Market cap $1.82B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Dynavax Technologies Corporation (DVAX). Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing novel vaccines. Its primary product is HEPLISAV-B, a hepatitis B vaccine, and it also manufactures and sells CpG 1018, an adjuvant used in vaccines.
Last analyzed: May 5, 2026These figures come from statements filed 13 months ago — the most recent this company has published.
Dynavax Technologies Corporation (DVAX) Healthcare & Pipeline Overview
More about this archive record
Can I still buy DVAX shares?
No. DVAX stopped trading on public markets in February 2026, so the shares are not available through a broker. Anything you see quoted for DVAX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before DVAX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Dynavax Technologies Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.